Neuland Laboratories · NSE: NEULANDLAB · BSE: 524558
Q4 FY26 results · Jan–Mar 2026
Neuland Laboratories reported revenue from operations of ₹776.25 crore (up 136.4% from Q4 FY25) and net profit of ₹212.67 crore (up 664.8% from Q4 FY25) for Q4 FY26 (Jan–Mar 2026), on a consolidated basis.
| Item | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 776.25 | 328.36 | +136.4% | 439.71 | +76.5% |
| Other income | 12.46 | 7.46 | +66.9% | 8.05 | +54.7% |
| Total income | 788.71 | 335.82 | +134.9% | 447.76 | +76.1% |
| Profit before tax | 287.49 | 39.30 | +631.5% | 54.48 | +427.8% |
| Net profit for the period | 212.67 | 27.81 | +664.8% | 40.57 | +424.2% |
| EPS, basic (₹) | 165.76 | 21.67 | +664.9% | 31.62 | +424.2% |
| Net margin (%) | 27.4 | 8.5 | 9.2 |
| Item | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 776.25 | 328.36 | +136.4% | 439.71 | +76.5% |
| Other income | 12.46 | 7.46 | +66.9% | 8.05 | +54.7% |
| Total income | 788.71 | 335.82 | +134.9% | 447.76 | +76.1% |
| Profit before tax | 287.04 | 38.98 | +636.4% | 54.27 | +428.9% |
| Net profit for the period | 212.52 | 27.73 | +666.3% | 40.42 | +425.8% |
| EPS, basic (₹) | 165.65 | 21.62 | +666.2% | 31.50 | +425.9% |
| Net margin (%) | 27.4 | 8.4 | 9.2 |
Consolidated
- Filed with BSE
- 12 May 2026, 21:09 IST
- Board meeting
- 12 May 2026
- Period
- 01 Jan 2026 to 31 Mar 2026
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 12 May 2026, 21:09 IST
- Board meeting
- 12 May 2026
- Period
- 01 Jan 2026 to 31 Mar 2026
- Review status
- Audited
- Source
- XBRL filing on BSE